Adocia Market Cap ($67.02 Million)
Market Cap & Net Worth: Adocia (ADOC)
Adocia market cap. Adocia (PA:ADOC) has a market capitalization of $67.02 Million (€57.33 Million) as of November 5, 2026. Listed on the PA stock exchange, this France-based company holds position #20558 globally and #319 in its home market, demonstrating a 19.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adocia's stock price €2.93 by its total outstanding shares 19565833 (19.57 Million). Also see Adocia (ADOC) cash conversion ratio for how efficiently the company converts equity into cash flow.
Adocia Market Cap History (2015–2026)
Adocia market cap history from 2015 to 2026. Data shows change from $1.67 Billion to $67.02 Million (-25.38% CAGR). Check ADOC stock price for real-time trading data and today's change.
Index Memberships
Adocia is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$222.02 Billion | 0.03% | #94 of 119 |
|
CAC Small90
CACS
|
$35.84 Billion | 0.19% | #44 of 64 |
|
CAC All-Tradable
CACT
|
$2.81 Trillion | 0.00% | #154 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.81 Trillion | 0.00% | #154 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.81 Trillion | 0.00% | #154 of 179 |
|
CAC Health Care
FRHC
|
$262.98 Billion | 0.03% | #25 of 36 |
Weight: Adocia's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adocia Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adocia's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Adocia growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
103.90x
Adocia's market cap is 103.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.40 Billion | $22.49 Million | -$7.89 Million | 62.05x | N/A |
| 2017 | $328.25 Million | $19.47 Million | -$8.55 Million | 16.86x | N/A |
| 2018 | $378.34 Million | $47.39 Million | $7.62 Million | 7.98x | 49.68x |
| 2019 | $226.46 Million | $2.14 Million | -$18.60 Million | 105.67x | N/A |
| 2020 | $189.86 Million | $841.00K | -$23.32 Million | 225.75x | N/A |
| 2021 | $185.28 Million | $1.44 Million | -$22.75 Million | 128.31x | N/A |
| 2022 | $90.81 Million | $11.45 Million | -$6.90 Million | 7.93x | N/A |
| 2023 | $263.97 Million | $2.15 Million | -$21.16 Million | 122.78x | N/A |
| 2024 | $137.48 Million | $9.32 Million | -$9.32 Million | 14.75x | N/A |
| 2025 | $153.26 Million | $1.48 Million | -$16.59 Million | 103.90x | N/A |
Competitor Companies of ADOC by Market Capitalization
Companies near Adocia in the global market cap rankings as of November 5, 2026. Also see Adocia balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Adocia by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Adocia (2015–2026)
Market capitalization of Adocia from 2015 to today. Between 2015 and today, Adocia's market cap moved from $1.67 Billion to $ 67.02 Million, with a yearly change of -25.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €67.02 Million | -56.27% |
| 2025 | €153.26 Million | +11.48% |
| 2024 | €137.48 Million | -47.92% |
| 2023 | €263.97 Million | +190.68% |
| 2022 | €90.81 Million | -50.99% |
| 2021 | €185.28 Million | -2.41% |
| 2020 | €189.86 Million | -16.16% |
| 2019 | €226.46 Million | -40.15% |
| 2018 | €378.34 Million | +15.26% |
| 2017 | €328.25 Million | -76.48% |
| 2016 | €1.40 Billion | -16.69% |
| 2015 | €1.67 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Adocia was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $67.02 Million USD |
| MoneyControl | $67.02 Million USD |
| MarketWatch | $67.02 Million USD |
| marketcap.company | $67.02 Million USD |
| Reuters | $67.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more